Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
Volume 1783, Issue 3, Pages 375-382Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbamcr.2007.12.003
Keywords
cholinergic anti-inflammatory pathway; cotinine; cytokine; inflammation; monocyte; PI3K-dependent anti-inflammatory pathway; tobacco smoking
Categories
Funding
- NIDCR NIH HHS [DE017680-01, R01 DE017680] Funding Source: Medline
- PHS HHS [H75/CCH424215-01] Funding Source: Medline
Ask authors/readers for more resources
Nicotine [(S)-3-(1-methyl-2-pyrrolidinyl)pyridine] is a major component of tobacco and a highly efficient acetylcholine receptor (nAChR) agonist that triggers the cholinergic anti-inflammatory pathway. We demonstrate that pre-treatment of monocytes with the stable nicotine catabolite, cotinine [(S)-1-methyl-5-(3-pyridinyl)-2-pyrrolidinone], dramatically alters the nature of the inflammatory response to Gram negative bacteria by abrogating the production of cytokines that are under the transcriptional control of the NF-kappa B system (TNF-alpha, IL-1 beta, IL-6, IL-12/IL-23 p40) and shifting the response towards an IL-10-dominated anti-inflammatory profile. This anti-inflammatory phenomenon is initiated specifically by engagement of the monocytic alpha 7 nAChR; and is PI3K/GSK-3 beta-dependent; but NF-kappa B-independent. These mechanistic insights suggest an ability to exploit convergent, endogenous anti-inflammatory pathway(s) to either upregulate or down-regulate the production of specific cytokine groups (pro- or anti-inflammatory cytokines) depending on the clinical necessity. (c) 2007 Elsevier B.V All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available